Εμφάνιση απλής εγγραφής

dc.creatorBertsias G., Karampli E., Sidiropoulos P., Gergianaki I., Drosos A., Sakkas L., Garyfallos A., Tzioufas A., Vassilopoulos D., Tsalapaki C., Sfikakis P., Panopoulos S., Athanasakis K., Perna A., Psomali D., Kyriopoulos J., Boumpas D.T.en
dc.date.accessioned2023-01-31T07:38:08Z
dc.date.available2023-01-31T07:38:08Z
dc.date.issued2016
dc.identifier10.1177/0961203316642310
dc.identifier.issn09612033
dc.identifier.urihttp://hdl.handle.net/11615/71614
dc.description.abstractAnalyses of the medical and economic burden of chronic disorders such as systemic lupus erythematosus (SLE) are valuable for clinical and health policy decisions. We performed a chart-based review of 215 adult SLE patients with active autoantibody-positive disease at the predefined ratio of 30% severe (involvement of major organs requiring treatment) and 70% non-severe, followed at seven hospital centres in Greece. We reviewed 318 patients consecutively registered over three months (sub-study). Disease activity, organ damage, flares and healthcare resource utilization were recorded. Costs were assessed from the third-party payer perspective. Severe SLE patients had chronic active disease more frequently (22.4% vs 4.7%), higher average SLE disease activity index (SLEDAI) (10.5 vs 6.1) and systemic lupus international collaborating clinics (SLICC) damage index (1.1 vs 0.6) than non-severe patients. The mean annual direct medical cost was €3741 for severe vs €1225 for non-severe patients. Severe flares, active renal disease and organ damage were independent cost predictors. In the sub-study, 19% of unselected patients were classified as severe SLE, and 30% of them had chronic active disease. In conclusion, this is the first study to demonstrate the significant clinical and financial burden of Greek SLE patients with active major organ disease. Among them, 30% display chronic activity, in spite of standard care, which represents a significant unmet medical need. © The Author(s), 2016.en
dc.language.isoenen
dc.sourceLupusen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84988699912&doi=10.1177%2f0961203316642310&partnerID=40&md5=539e5e7728a2d6eb0fa34a69c78a3d1d
dc.subjectantimalarial agenten
dc.subjectautoantibodyen
dc.subjectbosentanen
dc.subjectmycophenolate mofetilen
dc.subjectnonsteroid antiinflammatory agenten
dc.subjectphospholipid antibodyen
dc.subjectprednisoneen
dc.subjectrituximaben
dc.subjectautoantibodyen
dc.subjectadulten
dc.subjectcomorbidityen
dc.subjectcost of illnessen
dc.subjectdisease activityen
dc.subjectdisease exacerbationen
dc.subjectdisease severityen
dc.subjectfemaleen
dc.subjectfinancial managementen
dc.subjectGreeceen
dc.subjecthealth care costen
dc.subjecthealth care utilizationen
dc.subjecthumanen
dc.subjectkidney diseaseen
dc.subjectlupus erythematosus nephritisen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectmedical record reviewen
dc.subjectprevalenceen
dc.subjectpriority journalen
dc.subjectproteinuriaen
dc.subjectReviewen
dc.subjectSLEDAIen
dc.subjectsystemic lupus erythematosusen
dc.subjecteconomicsen
dc.subjectimmunologyen
dc.subjectLupus Erythematosus, Systemicen
dc.subjectmiddle ageden
dc.subjectretrospective studyen
dc.subjectseverity of illness indexen
dc.subjectAdulten
dc.subjectAutoantibodiesen
dc.subjectFemaleen
dc.subjectGreeceen
dc.subjectHealth Care Costsen
dc.subjectHumansen
dc.subjectLupus Erythematosus, Systemicen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectRetrospective Studiesen
dc.subjectSeverity of Illness Indexen
dc.subjectSAGE Publications Ltden
dc.titleClinical and financial burden of active lupus in Greece: A nationwide studyen
dc.typeotheren


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής